Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease Progression in Patients With Primary Progressive Multiple Sclerosis

Rhea-AI Summary

Quantum BioPharma (NASDAQ:QNTM) has signed an agreement with Ingenu CRO Pty to conduct a clinical study observing disease progression in patients with primary progressive multiple sclerosis. The study, announced on September 9, 2024, will be carried out through Quantum's subsidiary, HUGE Biopharma Australia Pty This observational study is a important step towards initiating a future phase 2 clinical trial with Lucid-21-302 (Lucid-MS), advancing Quantum's multiple sclerosis research program. Dr. Andrzej Chruscinski, VP of Scientific and Clinical Affairs at Quantum Biopharma, expressed enthusiasm about the collaboration, highlighting its importance in progressing their MS research efforts.

Positive

• Agreement signed with Ingenu CRO to conduct a clinical study on primary progressive multiple sclerosis
• Study will facilitate a future phase 2 clinical trial with Lucid-21-302 (Lucid-MS)
• Advances Quantum BioPharma's multiple sclerosis research program

Negative

• None.

TORONTO, ON / ACCESSWIRE / September 9, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces that through its subsidiary, HUGE Biopharma Australia Pty Ltd., it entered into an agreement with Ingenu CRO Pty Ltd on August 13, 2024 to conduct a clinical study to observe and quantify disease progression in patients with primary progressive multiple sclerosis. This study will facilitate a future phase 2 clinical trial with Lucid-21-302 (Lucid-MS).

"We are very pleased to be working with Ingenu CRO to conduct this observational study in patients with multiple sclerosis. This is an important study which advances our multiple sclerosis research program and moves us closer to initiating a phase 2 clinical trial with Lucid-21-302," said Dr. Andrzej Chruscinski, Vice-President, Scientific and Clinical Affairs at Quantum Biopharma.

Contact Information

Zeeshan Saeed
Founder, CEO and Executive Co-Chairman of the Board
zsaeed@quantumbiopharma.com
416-854-8884

SOURCE: Quantum Biopharma Ltd.

View the original press release on accesswire.com

FAQ

What is the purpose of Quantum BioPharma's new clinical study with Ingenu CRO?

The clinical study aims to observe and quantify disease progression in patients with primary progressive multiple sclerosis, facilitating a future phase 2 clinical trial with Lucid-21-302 (Lucid-MS).

When did Quantum BioPharma (QNTM) sign the agreement for the MS clinical study?

Quantum BioPharma signed the agreement with Ingenu CRO on August 13, 2024.

What is Lucid-21-302 in relation to Quantum BioPharma's research?

Lucid-21-302, also known as Lucid-MS, is a compound being developed by Quantum BioPharma for potential use in treating multiple sclerosis, targeted for a future phase 2 clinical trial.

Which subsidiary of Quantum BioPharma (QNTM) is involved in the MS clinical study?

HUGE Biopharma Australia Pty , a subsidiary of Quantum BioPharma, entered into the agreement with Ingenu CRO for the clinical study.